Clinical Trials Logo

Glabellar Lines clinical trials

View clinical trials related to Glabellar Lines.

Filter by:

NCT ID: NCT01608672 Completed - Glabellar Lines Clinical Trials

Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®

Start date: April 1, 2012
Phase:
Study type: Observational

This is an observational study assessing patient satisfaction following at least 5 years of BOTOX® treatment for glabellar lines.

NCT ID: NCT01271452 Completed - Glabellar Lines Clinical Trials

Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines

Start date: September 2010
Phase: Phase 4
Study type: Interventional

This study will evaluate the safety and efficacy of two different types of botulinum toxin type A for the treatment of glabellar frown lines.

NCT ID: NCT01224015 Completed - Glabellar Lines Clinical Trials

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

Start date: May 2011
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of botulinum toxin type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides) for patients who successfully completed Study 191622-099.

NCT ID: NCT01189760 Completed - Glabellar Lines Clinical Trials

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

Start date: September 1, 2010
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides)

NCT ID: NCT00512135 Completed - Glabellar Lines Clinical Trials

Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines

Start date: June 18, 2007
Phase: Phase 3
Study type: Interventional

The study objective was to investigate the safety and efficacy of incobotulinumtoxinA (Xeomin) during repeat dose treatment of glabellar frown lines. 801 participants with moderate to severe glabellar frown lines at maximum frown who completed participation in one of the studies in this program, i.e. MRZ 60201-0520/1, MRZ 60201-0527/1, MRZ 60201-0724/1, or MRZ 60201-0741/1 were eligible to participate in this repeat-dose study.

NCT ID: NCT00408785 Completed - Glabellar Lines Clinical Trials

A Study Of BOTOX For The Treatment Of Glabellar Lines

Start date: November 1, 2006
Phase: Phase 3
Study type: Interventional

This is a Multicenter, double-blind, randomized, placebo-controlled, parallel-group comparative study to confirm the efficacy and safety of BOTOX 20 units single injection for the Chinese patients with glabellar lines. The subjects will receive a single intramuscular treatment consisting of 5 injections of either BOTOX? 20U or placebo.